ICMJE DISCLOSURE FORM

Date: 3/12/2021

Your Name: Kaitlyn DeHority

Manuscript Title: Prophylactic Surgical Treatment Using CT-Based Rigidity Analysis vs After the Fact Fracture Treatment

of Pathologic Femoral Lesions

Manuscript number (if known): AOJ-2020-BM-02 (AOJ-20-92)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastxNone	36 months
4	Royalties or licenses Consulting fees	xNonexNone	

5	Payment or honoraria for	x_None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	in other board, society,	xNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x_None	
12	Receipt of equipment, materials, drugs, medical	x_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	x_None	

Please summarize the above conflict of interest in the following box:

Kaitlyn De	Hority reports no suppo	rt or conflicts of intere	est.	

Please place an "X" next to the following statement to indicate your agreement:

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 3-22-21

Your Name: Tina Craig

Manuscript Title: Prophylactic Surgical Treatment Using CT-Based Rigidity Analysis vs After the Fact Fracture Treatment

of Pathologic Femoral Lesions

Manuscript number (if known): AOJ-2020-BM-02 (AOJ-20-92)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_xNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	xNone	
4	Consulting fees	xNone	

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_xNone	
	testimony		
7	Support for attending	_xNone	
	meetings and/or travel		
8	Patents planned, issued or	x None	
0	pending	xNone	
	pending		
9	Participation on a Data	x None	
9	Safety Monitoring Board or	xNone	
	Advisory Board		
10	Leadership or fiduciary role	x None	
10	in other board, society,	xNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
11	Stock of Stock options		
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

Tina Craig does not report any conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: March 22, 2021

Your Name: Timothy A. Damron

Manuscript Title: Prophylactic Surgical Treatment Using CT-Based Rigidity Analysis vs After the Fact Fracture Treatment

of Pathologic Femoral Lesions

Manuscript number (if known): AOJ-2020-BM-02 (AOJ-20-92)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Musculoskeletal Tumor Society Research Grant/OREF NIH, Jim and Juli Boeheim Research Grant, Carol Baldwin Research Grant, Page Industries Research Grant, Stryker Industries Research Grant, Cerament Clinical Research, Wright medical
3	Royalties or licenses	None	Lippincott, Williams, Wilkins (Author of Textbook)

4	Consulting fees	None	BoneSupport Orthopedics Physician Advisory Board
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	_XNone	Occasional, unrelated
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	None	Orthopedic Retractor Adaptor Device (issued) Two orthopedic surgical devices/equipment (planned)
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	Journal of American Academy of Orthopedic Surgeons- Editor Board-research; Editor Boards: Journal of Orthopedic Research, Clin.Orthopedics the Onlind Orthopedics Journal; Medicina, BMC-Musculoskeletal disorders
11	Stock or stock options	x_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_xNone	
13	Other financial or non- financial interests	None	David G. Murray Endowment (Institutional Research Grant Support)

Please summarize the above conflict of interest in the following box:

Other than the Musculoskeletal Tumor Society funding which has long since been completed and ongoing related work examining other aspects of fracture risk prediction, none of the other represent related sources of conflicts

Please place an "X" next to the following statement to indicate your agreement:
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.